Stable and reusable calcium-responsive biopolymer for affinity precipitation of therapeutic antibodies
- Authors
- Park, Heesun; Oh, Jeong-Seok; Lee, Jonghwan; Bang, Jinho; Park, Keunwan; Jeong, Suhyeon; Park, Seho; Woo, Jae-Sung; Kim, Sunghyun
- Issue Date
- 2024-08
- Publisher
- Cold Spring Harbor Laboratory Press
- Citation
- Protein Science, v.33, no.8
- Abstract
- Affinity precipitation is an attractive method for protein purification due to its many advantages, including the rapid capture of target proteins, simple processing, high specificity, and ease of scale-up. We previously reported a robust antibody purification method using Ca2+-dependent precipitation of ZZ-hCSQ2, a fusion protein of human calsequestrin 2, and the antibody-binding protein ZZ. However, the stability of this fusion protein was not sufficiently high for industrial use because the antibody recovery yield decreased to 60% after being reused 10 times. To identify a more stable calsequestrin (CSQ), we calculated Rosetta energy values for the folding stabilities of various CSQ homologs and selected human CSQ1 (hCSQ1) with lowest energy value (-992.6) as the new CSQ platform. We also identified that the linker sequence between ZZ and CSQ was vulnerable to proteases and alkaline pH by N-terminal protein sequencing. Therefore, we changed the linker to four asparagine (4N) sequences, which were shorter and less flexible than the previous glycine-rich linker. The new version of ZZ-CSQ, ZZ-4N-hCSQ1, was stable in a protease-containing conditioned medium obtained from the cultured Chinese hamster ovary cell or high pH condition (0.1M sodium hydroxide) for more than 5 days and could be reused at least 25 times for antibody purification without loss of recovery yield. The antibodies purified by ZZ-4N-hCSQ1 precipitation also showed greater purity (similar to 33.6-fold lower host cell DNA and similar to 6.4-fold lower host cell protein) than those purified by protein A chromatography. These data suggest that ZZ-4N-hCSQ1 precipitation is more efficient and can achieve cost-effectiveness of up to 12.5-fold cheaper than previous antibody purification methods and can lower the production costs of therapeutic antibodies.
- Keywords
- LIGAND; MONOCLONAL-ANTIBODY; PROTEIN-A; PURIFICATION; CALSEQUESTRIN; antibody purification; calcium-dependent; calsequestrin; cost-effectiveness; protein engineering; reuse; Z-domain
- ISSN
- 0961-8368
- URI
- https://pubs.kist.re.kr/handle/201004/150371
- DOI
- 10.1002/pro.5066
- Appears in Collections:
- KIST Article > 2024
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.